Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
about
[Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].Outcomes of adding second hypoglycemic drug after metformin monotherapy failure among type 2 diabetes in Hungary.Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records.Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.Long-Term Efficacy and Safety of Empagliflozin Monotherapy in Drug-Naïve Patients with Type 2 Diabetes in Indian Subgroup: Results from a 76-week Extension Trial of Phase III, Double-Blind, Randomized Study.Synthesis and biological evaluation of novel ursolic acid analogues as potential α-glucosidase inhibitors.A review of gliptins in 2011.Cardiovascular effects of gliptins.Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.Efficacy and safety of Jentadueto® (linagliptin plus metformin).Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Development of RP-HPLC, Stability Indicating Method for Degradation Products of Linagliptin in Presence of Metformin HCl by Applying 2 Level Factorial Design; and Identification of Impurity-VII, VIII and IX and Synthesis of Impurity-VII.Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design.The potential role of vildagliptin in the management and prevention of type 2 diabetes mellitus.Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: Results from observational GLOBE Study.
P2860
Q33858415-546F5BA9-2EB7-40DB-93C1-BA7796593751Q37010393-247B51FD-6E82-4B40-92E5-8E3084EA60F4Q37239286-B5583F68-8F5E-4A49-ABAD-411C78A42C33Q37598258-81A116CF-CE2F-4B08-ABDB-28870251F4ACQ37721942-F359CA11-9614-490E-9D88-374CEB2027C3Q37728361-8DE01B9C-80FD-48D0-9C28-D998C784A043Q37965612-691814B5-C575-4256-A43B-2432E29DE7C9Q38072259-4197EEF6-DFA7-4249-9810-50CBB45E81DAQ38078436-57A1E5A2-ABD2-478A-B7AF-90CE8D4C942DQ38082848-CB258555-6427-499B-9E39-88A13268EC85Q38113092-0F10DFFE-38BA-48ED-BB02-4934E3983607Q38707307-9C44B7F1-E3C7-448D-AB73-CB4096A4C4E7Q40243211-0847F1DC-5087-4A1C-A123-870BF19069EAQ42575070-8D845CDB-FEAE-494A-86C9-B65BF9326013Q43096989-4B0B07AD-0B0C-454F-A407-4BBEA3DE91B4
P2860
Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Antidiabetic medications in ov ...... ased treatment on body weight.
@en
type
label
Antidiabetic medications in ov ...... ased treatment on body weight.
@en
prefLabel
Antidiabetic medications in ov ...... ased treatment on body weight.
@en
P2860
P1476
Antidiabetic medications in ov ...... based treatment on body weight
@en
P2093
P2860
P356
10.1111/J.1742-1241.2007.01441.X
P50
P577
2007-08-01T00:00:00Z